After treatment with tyrosine kinase inhibitors, dying sensitive melanoma and lung cancer cells secrete into the extracellular space components that stimulate chemoresistance and metastasis of recipient tumor cells due to activation of the PI3K/AKT/mTOR pathway [191]. Here, MTOR is linked to neoplasm.